Skip to main content
. 2022 Feb 23;14(5):1147. doi: 10.3390/cancers14051147

Table 2.

Ranking of outcome categories per study.

STUDY Methods Outcome Categories
Author Year Elicitation Method Quality of Life Transient Short Term Side Effects Severe and Persistent Side Effects Treatment Response Progression- and Disease-Free Survival Overall Survival
Curative Setting Studies
Pieterse [25] 2007 CA 5 4 3
Thrumurthy [27] 2011 DCE 5 3 4 2
Mohamed [26] 2011 DCE 3 4 5
* Jorgensen [28] 2013 Rating scale 3 2 2 5 4
Molinari [29] 2014 Trade-off 2 5 4 3
Thill [16] 2016 AHP 2 3 5 4
Bröckelmann [46] 2019 DCE 2 4 5 3
van der Valk [30] 2020 CA 4 5 3 3
Khan [51] 2020 DCE 5 3 4
Werner [31] 2021 Rating scale 4 2 1 3 3 5
Palliative Setting Studies
Havrilesky [33] 2014 DCE 4 3 2 5
DaCosta [34] 2014 CA 3 2 4 5
Park [32] 2012 DCE 5 4 3
Muhlbacher [35] 2015 DCE 3 2 5 5
* Uemura [36] 2016 DCE 4 1 5 2 3
* Chau [37] 2016 Rating scale 4 1 5 3 2
Gonzalez [38] 2017 DCE 3 5 4
Liu [39] 2019 DCE 4 3 2 5
Bröckelmann [46] 2019 DCE 2 3 5 4
Wong [40] 2020 DCE 4 5 3
Khan [50] 2020 DCE 4 3 5
* Stegmann [41] 2020 OPT 5 3 4
Weilandt [42] 2021 DCE 3 2 4 1 5
Both Settings Studies
Johnson [43] 2006 CA 5 3 4
Schmidt [44] 2017 DCE 4 3 5
Sun [45] 2019 DCE 2 3 4 5
* Festen [47] 2019 OPT 5 3 4
Fifer [49] 2020 DCE 3 3 4 5
Valenti [48] 2020 CA 4 3 3 5
* Festen [50] 2021 OPT 5 3 4

Higher numbers represent higher priority (range 0–5). Where an outcome category is not assessed, no number appears. CA = conjoint analysis, DCE = discrete choice experiment, AHP = Analytic hierarchy process, OPT = outcome prioritization tool. * Studies with median age above 70 or separate data for this subgroup.